Anondita Medicare has issued a second corrigendum to the notice of its 01/2026-27 Extraordinary General Meeting (EGM), scheduled for May 28, 2026. The revision addresses a change in the valuation working under Regulation 164 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, leading to an adjustment in the applicable 90 trading day price-band period. The company informed the National Stock Exchange of India (NSE) that a revised valuation report has been obtained from the Registered Valuer.

The Board has fixed the issue price at ₹1,038 per warrant, which remains above the minimum price determined by the Registered Valuer. The valuation parameters include book value and comparable trading multiples. The corrigendum updates Point No. 6 of the explanatory statement regarding the basis of price determination and Point No. 23 concerning the Practicing Company Secretary’s Certificate.

Terms of the Preferential Issue

The EGM seeks shareholder approval to allot up to 2,85,000 convertible warrants to promoter Anupam Ghosh. Each warrant is convertible into one fully paid-up equity share with a face value of ₹10. The total issue size aggregates to ₹29,58,30,000.

Payment for the warrants is structured in two tranches. A minimum of 25% of the warrant issue price, amounting to ₹7,39,57,500, must be paid at the time of subscription and allotment. The remaining 75%, totaling ₹22,18,72,500, is payable upon the exercise of the right to convert the warrants into equity shares within 18 months from the date of allotment.

Valuation and Certification

The revised valuation was performed by Mr. Ankush Garg, a Registered Valuer (Registration No. IBBI/RV/02/2018/10010). The revised certificate confirming the minimum price is available for inspection at the Registered Office and on the company’s website. Additionally, the certificate from Mr. Mohit Singhal, Practicing Company Secretary (FCS 11143 | CP 15995), certifying compliance with SEBI ICDR Regulations, has been updated and made available to members.

Anondita Medicare Limited has announced its participation in Pharma Eurasia 2026, Uzbekistan, a leading pharmaceutical industry exhibition. The event is scheduled to be held from 20th May 2026 to 22nd May 2026 at Tashkent Pharma Park, Tashkent, Uzbekistan. The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Event Details

The company will participate in the exhibition in physical mode, with the primary objective of expanding its presence across Central Asian countries and exploring business opportunities, including engagement with potential buyers. The key details of the event are outlined below:

Strategic Objectives

Anondita Medicare's participation in the exhibition is aligned with its broader international expansion strategy. The company intends to leverage the platform to achieve the following objectives:

• Strengthening the company's presence across Central Asian markets
• Exploring engagement opportunities with potential buyers and channel partners
• Showcasing the company's manufacturing capabilities and product portfolio in international markets
• Expanding global business visibility through participation in a leading pharmaceutical industry exhibition

Management Commentary

Commenting on the development, Mr. Anupam Ghosh, Managing Director, Anondita Medicare Limited, said: "Our participation in Pharma Eurasia 2026 reflects our continued focus on expanding our international presence and engaging with potential business partners across emerging markets. The exhibition provides an opportunity to showcase our manufacturing capabilities and explore growth opportunities in Central Asia."

About Anondita Medicare Limited

Anondita Medicare Limited is an Indian manufacturer of condoms, operating under its flagship brand "COBRA." The company runs its own manufacturing facility and follows a quality-driven, compliant production model. The company is led by Mr. Anupam Ghosh, who brings over 25 years of experience in the healthcare and contraceptive products industry. With a strong domestic presence, particularly in North India, Anondita Medicare is actively expanding its geographical footprint across India and international markets. Ongoing initiatives such as automation-led capacity enhancement and patented female condom products position the company for scalable growth and long-term value creation.